Jul 17, 2025
Even weeks after ASCO 2025, the ripple effects of new data are still visible across the oncology digital landscape. Using Navigator365 Matrix, we analyzed what leading Digital Opinion Leaders (DOLs) were saying online about emerging data in both breast cancer and B-cell lymphoma.
Across nearly 3,000 congress-specific posts, key voices helped elevate new treatment regimens, spotlight clinical trials, and shape how the medical community is processing innovation.
From Data Drops to Digital Impact
With strong engagement across 100+ top oncology influencers, breast and blood cancer content saw significant reach and resonance—especially around first-line treatment shifts and paradigm-changing trials.
What Clinicians Were Talking About:
In Breast Cancer:
- ASCENT-04: Trodelvy + Keytruda reduced risk of progression by 35% in PD-L1+ TNBC
- SERENA-6 & EMBER-3: Oral SERDs like Camizestrant and Imlunestrant generated optimism around replacing older endocrine therapies
- VERITAC-2: Vepdegestrant offered promising benefit for ESR1-mutated tumors
- SYMPATICO & STARGLO: DOLs highlighted new data around fixed-duration and non-CAR-T regimens for relapsed patients
- Zanubrutinib + Venetoclax: A strong 1L combo gaining digital traction
- DETERMINE & RITZ: Showed enthusiasm around personalized therapy and chemo-free approaches
Why It Matters for HCP Marketers
When DOLs start talking, their reach travels fast. Posts citing new clinical trial data saw significant amplification, while the most engaged oncologists emerged as key digital amplifiers. Understanding these signals helps HCP marketers anticipate sentiment shifts—and align their messaging accordingly.
Unlock the Full Insights
This full report surfaces:- Which DOLs led the conversation in breast and B-cell oncology
- What treatments and trials dominated social discussions
- How real-time insights from Navigator365 Matrix can support your strategy